Difference between revisions of "Vinflunine (Javlor)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Intravenous chemotherapy" to "Category:Intravenous medications") |
m |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=419548 NCI drug dictionary]: A bi-fluorinated derivative of the semi-synthetic vinca alkaloid vinorelbine with antitubulin, antineoplastic, and antiangiogenic activities. Vinflunine inhibits tubulin assembly without any stablization of assembled microtubules at concentrations comparable to those of other vinca alkaloids such as vincristine, vinblastine and vinorelbine; this effect on microtubule dynamics results in cell cycle arrest in mitosis and apoptosis. Compared to other vinca alkaloids, this agent binds weakly to the vinca-binding site, indicating that vinflunine may exhibit reduced neurotoxicity. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=419548 NCI drug dictionary]: A bi-fluorinated derivative of the semi-synthetic vinca alkaloid vinorelbine with antitubulin, antineoplastic, and antiangiogenic activities. Vinflunine inhibits tubulin assembly without any stablization of assembled microtubules at concentrations comparable to those of other vinca alkaloids such as vincristine, vinblastine and vinorelbine; this effect on microtubule dynamics results in cell cycle arrest in mitosis and apoptosis. Compared to other vinca alkaloids, this agent binds weakly to the vinca-binding site, indicating that vinflunine may exhibit reduced neurotoxicity. | ||
| − | = | + | ==Diseases for which it is used== |
| − | + | *[[Breast cancer]] | |
| + | *[[Urothelial carcinoma]] | ||
| − | + | ==History of changes in EMA indication== | |
| − | [[Category: | + | *2009-09-21: Initial marketing authorization at Javlor. |
| + | |||
| + | ==Also known as== | ||
| + | *'''Brand name:''' Javlor | ||
| + | |||
| + | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | [[Category:Vesicant | + | [[Category:Vesicant]] |
[[Category:Microtubule inhibitors]] | [[Category:Microtubule inhibitors]] | ||
[[Category:Vinca alkaloids]] | [[Category:Vinca alkaloids]] | ||
| + | |||
| + | [[Category:Breast cancer medications]] | ||
| + | [[Category:Urothelial carcinoma medications]] | ||
| + | |||
| + | [[Category:EMA approved in 2009]] | ||
Latest revision as of 13:34, 9 September 2023
Mechanism of action
From the NCI drug dictionary: A bi-fluorinated derivative of the semi-synthetic vinca alkaloid vinorelbine with antitubulin, antineoplastic, and antiangiogenic activities. Vinflunine inhibits tubulin assembly without any stablization of assembled microtubules at concentrations comparable to those of other vinca alkaloids such as vincristine, vinblastine and vinorelbine; this effect on microtubule dynamics results in cell cycle arrest in mitosis and apoptosis. Compared to other vinca alkaloids, this agent binds weakly to the vinca-binding site, indicating that vinflunine may exhibit reduced neurotoxicity.
Diseases for which it is used
History of changes in EMA indication
- 2009-09-21: Initial marketing authorization at Javlor.
Also known as
- Brand name: Javlor